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Background: Childhood cancer relies heavily on inpatient hospital services to deliver tumor-directed therapy and
manage toxicities. Hospitalizations have increased over the past decade, though not uniformly across childhood
cancer diagnoses. Analysis of the reasons for admission of children with cancer could enhance comparison of
resource use between cancers, and allow clinical practice data to be interpreted more readily. Such comparisons
using nationwide data sources are difficult because of numerous subdivisions in the International Classification of
Diseases Clinical Modification (ICD-9) system and inherent complexities of treatments. This study aimed to develop
a systematic approach to classifying cancer-related admissions in administrative data into categories that reflected
clinical practice and predicted resource use.
Methods: We developed a multistep algorithm to stratify indications for childhood cancer admissions in the Kids
Inpatient Databases from 2003, 2006 and 2009 into clinically meaningful categories. This algorithm assumed that
primary discharge diagnoses of cancer or cytopenia were insufficient, and relied on procedure codes and secondary
diagnoses in these scenarios. Clinical Classification Software developed by the Healthcare Cost and Utilization
Project was first used to sort thousands of ICD-9 codes into 5 mutually exclusive diagnosis categories and 3
mutually exclusive procedure categories, and validation was performed by comparison with the ICD-9 codes
in the final admission indication. Mean cost, length of stay, and costs per day were compared between categories
of indication for admission.
Results: A cohort of 202,995 cancer-related admissions was grouped into four categories of indication for admission:
chemotherapy (N=77,791, 38%), to undergo a procedure (N=30,858, 15%), treatment for infection (N=30,380, 15%),
or treatment for other toxicities (N=43,408, 21.4%). The positive predictive value for the algorithm was >95% for each
category. Admissions for procedures had higher mean hospital costs, longer hospital stays, and higher costs per day
compared with other admission reasons (p<0.001).
Conclusions: This is the first description of a method for grouping indications for childhood cancer admission within
an administrative dataset into clinically relevant categories. This algorithm provides a framework for more detailed
analyses of pediatric hospitalization data by cancer type.
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Approximately 18,000 children under 19 years old are di-
agnosed with a childhood cancer annually in the United
States [1]. One quarter of these children have leukemia,
and other common diagnoses include lymphomas, cen-
tral nervous system tumors, sarcomas, and neuroblast-
oma. Dramatic improvements in survival over the past
few decades have resulted from use of complex multi-
modal therapies, often associated with high risks of side
effects. These medically intense treatments rely heavily on
inpatient hospital resources. As the focus on healthcare
utilization increases, understanding the resources required
to treat children with cancer becomes more critical.
Inpatient hospital needs for childhood cancer have
grown at different rates by diagnoses. Price et al. identified
admissions of children with cancer as the primary dis-
charge diagnosis and compared the mean costs in 2000
and 2009. In 2009, the overall mean cost per cancer-
related admission was $40,400 and had increased by 36%
from 2000 after accounting for inflation. The mean cost
per Hodgkin lymphoma admission increased by 12% to
$28,400, central nervous system tumor admissions in-
creased by 61% to $39,400, and leukemia admissions by
32.3% to $55,700 during this same period [2]. Berry et al.
described a 3% decrease in the prevalence of admission
of children with a diagnosis of bone malignancies from
2004 to 2009, while the prevalence of admission of chil-
dren with a diagnosis of acute non-lymphoid leukemia
increased 10.6% [3]. Changes in the incidence of new can-
cer diagnoses are insufficient to explain these differ-
ences by disease [1], suggesting that changes in clinical
practice play a major role. However, the complex nature
of multiple cancer diagnoses, treatments, and toxicities,
combined with limited research resources, means that
some prioritization for studying clinical practices is re-
quired. Therefore, we wanted to identify changes in the
patterns of childhood cancer admissions at a national level
that may account for the differences in hospital costs and
prevalence with the aim of identifying areas with the
greatest increases for future studies.
The current evidence for increased use of inpatient re-
sources is difficult to relate to oncology practice. Both
Price et al. and Berry et al. used cancer diagnoses to dis-
tinguish between admissions. However, childhood cancer
is a chronic condition and not, in itself, a reason for hos-
pital admission. Most admissions for cancer are for sched-
uled treatment (e.g., to receive chemotherapy) or are
unplanned for management of toxicities arising from can-
cer or its treatment [4-7]. Anticipated treatment regimens
are often determined at a national cooperative group level
and directly influence the frequency and severity of toxic-
ities [8,9]. The reason for admission is a major determin-
ant of the type and amount of resources used [10,11]. For
example, patients admitted for chemotherapy will usuallyreceive their pre-determined chemotherapy and be dis-
charged quickly, whereas patients admitted for treatment
of an infection are at higher risk of needing intensive care
services [12].
Numerous prospective childhood cancer clinical trials
have described treatment requirements and toxicities.
This type of research has limited application to the study
of childhood cancer hospitalizations as a whole [13,14]
because it only captures patients and events associated
with individual trials. Less than half of children enroll on
clinical trials when first diagnosed with cancer [15,16]
and this subset may not be wholly representative of the
childhood cancer population. Adolescents have historic-
ally been underrepresented on clinical trials [15,17] and
children with pre-existing medical conditions are less
likely to be eligible for participation [16]. Clinical trials
must be available for the patient’s cancer, a limiting fac-
tor for patients with rare tumors or those receiving care
at institutions not participating in childhood cancer clin-
ical trials [15]. Furthermore, focusing on clinical trials
will fail to capture palliative or end-of-life care, an im-
portant and costly part of medical services for childhood
cancer [18]. Administrative data, or data passively col-
lected for other indications, provides access to a more
diverse population of patients and may be more accurate
for studying admission patterns on a national level [19].
The Kids Inpatient Database (KID), compiled by the
Healthcare Quality and Utilization Project (HCUP) and
sponsored by the Agency for Healthcare Research and
Quality, is a nationally representative database that sam-
ples approximately 80% of pediatric discharges from
community hospitals in the United States. A version is
produced every 3 years and contains between 2.5 and
3.4 million de-identified admission records from 4,839
to 5,128 hospitals in 36 to 44 states [20]. All administra-
tive datasets pose challenges, including the structure and
quality of the data and generalizability [21]. KID uses
hospital admission as the primary unit of data; patients
are de-identified and repeat admissions cannot be
accounted for, and diagnoses and procedures are defined
by billing codes. However, these limitations are balanced
by the possibility of generating national hospitalization
estimates.
Administrative datasets that rely on billing codes pose
two challenges for studying complex diseases. The first
is the assignment of the primary discharge diagnosis by
coders remote from the clinical treatment team [21].
The second is the quantity of possible individual codes.
The 9th version of the International Statistical Classifica-
tion of Diseases and Related Health Problems (ICD-9)
coding system includes approximately 12,000 diagnostic
and 3,500 procedure codes. Furthermore, codes change
over time. To facilitate analysis using ICD codes, HCUP
developed Clinical Classification Software (CCS) which
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exclusive diagnostic groups and 231 mutually exclusive
procedure groups [22]. Most of the CCS groups repre-
sent fairly homogenous diagnoses or procedures, but
others combine conditions or procedures within a body
system [22]. CCS groups were developed for use across a
broad spectrum of potential diagnoses and may not
reflect a particular clinical situation such as childhood
cancer [23].
To study childhood cancer admission patterns and
trends on a national level, we first sought to develop a sys-
tematic approach to classifying cancer-related admissions
from administrative data into categories that reflected
clinical practice. The following report describes a multi-
step process for stratifying the indication for hospital
admission into four categories: chemotherapy, to undergo
a procedure, treatment for infection, or treatment for
other toxicities. To overcome the challenges of sorting
thousands of potential ICD-9 diagnostic and procedure
codes, the 491 CCS groups were incorporated into the al-
gorithm as an initial step in its development. To validate
the accuracy of the CCS in correctly allowing admis-
sions to be sorted into the four indications for admis-
sion, the ICD-9 codes in each category were individually
reviewed after assignment. Finally, to test our assumption
that utilization would be related to the indication for ad-
mission, mean estimates of utilization measures and rates




A cohort of cancer-related admissions was identified
from the full KID dataset for the years 2003, 2006, and
2009 (Figure 1A). Each KID admission contained up to
15 discharge diagnoses in 2003 and 2006, and 25 dis-
charge diagnoses in 2009. Cancer-related admissions
were defined as any admission with a cancer diagnosis
(CCS diagnostic groups 11 to 43) in any of the discharge
diagnoses [2]. All other admissions were excluded from
further analysis. In addition to diagnostic codes, each
admission contained up to 15 procedural codes, basic
demographic information on the patient (i.e., age, sex,
healthcare payer), status of the patient upon discharge
(i.e., alive or dead), and hospital location by state. States
participating in HCUP elect to submit patient race/
ethnicity data and the hospital day on which procedures
occurred. Utilization data on each admission included
length of stay (LOS) and total admission charge. This de-
identified dataset was considered exempt from human
subjects review by the institutional review board of the
Houston branch of the University of Texas Health Science
Center. The dataset was accessed after completion of a
data use agreement with HCUP.Admission indication definitions and algorithm
development
Definitions of clinically meaningful diagnostic categories,
procedure categories, and admission indications were de-
veloped by consensus by a group of four pediatric oncolo-
gists (HR, FO, KK, MS) and a pediatric oncology surgeon
(EK), all but one with experience in clinical processes
through formal professional development. In addition, two
members held clinical management roles, two with ad-
vanced training in epidemiology and one with advanced
training in health economics/health services research.
Clinical experience and relevant literature supported
four distinct indications for hospitalization of a child with
cancer: to deliver chemotherapy (Intent-Chemotherapy),
to perform a procedure (Intent-Procedure), to treat an in-
fection (Intent-Infection), or to manage a non-infectious
toxicity (Intent-Toxicity). Our approach to categoriz-
ing admissions into these four indications required
two main assumptions. First, we assumed that a discharge
diagnosis of cancer or cytopenia (i.e., neutropenia, anemia,
thrombocytopenia) did not provide a sufficient reason for
admission: cancers are chronic conditions and cytopenias
are managed in an outpatient setting in the absence of
other complications. Second, we assumed that when the
primary discharge diagnosis did not sufficiently describe
the reason for admission, the secondary discharge diagno-
sis would be an adequate substitute [24].
We defined an indication for each admission according
to a stepwise mutually exclusive algorithm (Figure 1B). The
first two indications, Intent-Chemotherapy and Intent-
Procedure, were identified by the performance of chemo-
therapy or a cancer-related procedure, respectively, during
the first 2 days of hospitalization. Intent-Chemotherapy
was identified first so that admissions that included minor
procedures performed prior to, but not delaying, chemo-
therapy would be considered chemotherapy admissions
rather than procedure admissions. The third and fourth
indications, Intent-Infection and Intent-Toxicity, were
identified from the remaining admissions by the presence
of an infection or non-infectious toxicity code, respect-
ively, as the primary discharge diagnosis or the secondary
discharge diagnosis if the primary discharge diagnosis
was a cancer or cytopenia. Intent-Infection admissions
were identified before Intent-Toxicity to allow admis-
sions with a primary diagnosis of cytopenia and a secondary
diagnosis of infection to be classified as an Intent-Infection
admission.
CCS categories and validation
To implement the above algorithm, each primary and sec-
ondary discharge diagnostic code and each procedure code
needed to be categorized into five diagnostic categor-
ies (malignancy, chemotherapy, infection, non-infectious
toxicities, and other) and three procedure categories
Figure 1 Multi-step algorithm for stratifying childhood-cancer admissions. (A) Identification of a cohort of cancer-related admissions from
the full KID dataset. (B) Stratification of admissions into indications for admissions. KID indicates Kids Inpatient Database; CCS indicates Clinical
Classification Software. &: Includes admissions with chemotherapy as primary procedure from states with no reported procedure dates. ^:
Excludes CCS diagnostic group 237 non-infectious ICD-9 codes and non-cytopenia toxicities.
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therapy is defined as both a procedure and diagnosis
within the CCS and ICD-9 systems. This categorization
was performed using the 491 CCS groups after examin-
ation by the physician group (HR, FO, KK, MS, EK) of
the definition of each CCS group and the ICD-9 codes it
contained. The complete categorization is presented in
Additional file 1: Table S1. CCS diagnostic groups 11
through 43 were categorized as malignancy and CCS
group 45 was categorized as chemotherapy. CCS diag-
nostic groups were categorized as infections if they in-
cluded definitive or presumed infections by any microbe,fever, and/or shock. CCS diagnostic groups were catego-
rized as non-infectious toxicities if they included tox-
icities arising from the cancer pathology or treatment
for the cancer not previously categorized as infection, and
were further sub-classified into cytopenias (CCS diagnos-
tic groups 59, 60, and 62–64) and non-cytopenic toxicities
(all others). CCS diagnostic group 237 (“Complication
of device, implant or graft”) was subdivided into in-
fections (ICD-9 999.31, 996.62, 996.67, 996.69) and non-
infections (all others) as it contained large proportions
of both. Diagnostic groups not related to the malignancy
were categorized as “other”. Such diagnoses included








<1 y 6,722 (3.3%)
1 to 4 y 48,461 (23.9%)
5 to 9 y 43,523 (21.4%)
10 to 14 y 42,801 (21.1%)












Other (Asian, Native American, “other”) 14,782 (7.3%)




Non-Infectious toxicity 40,725 (20.1%)
Other 9,293 (4.6%)
&Represents both Medicaid and Medicare; ^Percentages do not sum to 100
owing to missing data. CCS indicates Clinical Classification Software.
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established pediatric diagnoses, mental/behavioral dis-
orders, and trauma. Chemotherapy procedures were lim-
ited to CCS procedure group 224. Other CCS procedure
groups were categorized as cancer-related procedures if
they included any procedure for the diagnosis or treatment
of the malignancy or management of a treatment-related
toxicity. Imaging studies and blood product transfusions
were excluded. See Additional file 2 for a do-file of the
CCS classification and algorithm.
To validate the accuracy of the CCS in correctly sort-
ing admissions into admission indication categories, the
ICD-9 codes for the primary and secondary discharge
diagnoses and procedures occurring in the first 2 days of
hospitalization were reviewed after admissions were
assigned. Review of the individual codes was limited to
the 90% most frequent ICD-9 codes or codes appearing
more than once within that admission indication, which-
ever limit was achieved first. The initial sorting and review
of ICD-9 codes was performed by a pediatric oncologist
(HR). The clinical team then reviewed the categorization
and any conflicts were resolved by discussion until con-
sensus was obtained. The positive predictive value (PPV)
of each admission indication as sorted by CCS groups was
determined by calculating the percentage of the true posi-
tives (i.e., admissions with ICD-9 codes appropriate for
the admission indication) within each admission cat-
egory. Sensitivity was further determined by identifying
admissions mis-classified by CCS groupings. We desired
the algorithm to have a PPV of ≥ 95%. Because admission
numbers were large, 95% confidence intervals (CI) were
determined using simple asymptotic methods [25]. All
analysis was performed on STATA version 11 (Stata Corp.,
College Station, TX, USA).
Comparison of admission indications
We compared the admission indications by frequency of
resource-intense events and utilization measures using
descriptive statistics and analysis of variance. Admissions
associated with hematopoietic stem cell transplantation
(HCT) or requiring intensive care unit (ICU) support are
resource intense events occurring frequently in childhood
cancer treatment [10,12,26,27]. Admissions associated
with HCT were defined as those including a CCS proced-
ure code 64 (ICD-9 41.xx). Admissions associated with
ICU services were defined as those with diagnostic codes
of respiratory arrest (CCS 131), cardiac arrest (CCS 107)
or shock (CCS 249). Total admission costs were estimated
by converting charges to costs using cost-to-charge ratios
[28]. A mean cost per day for each admission was calcu-
lated as the quotient of total cost of admission over LOS.
All costs were inflated to 2009 US$ using the All-Urban
Consumer Price Index [29]. A p-value < 0.05 was consid-
ered significant.Results
Overall cancer subset
We identified 202,995 admissions with a cancer diagno-
sis from the 2003, 2006 and 2009 KIDs. Characteristics
of these admissions are presented in Table 1.
Admission indication
The cohort of childhood cancer admissions (Figure 1A)
was sorted into admission indications using CCS diagnos-
tic and procedure categories (Figure 1B). Review of the
ICD-9 codes of the admissions in each indication validated
the accuracy of this sorting process. The distribution of
admissions by indication is presented in Table 2.
Intent-Chemotherapy admissions were identified first
from the entire cancer cohort. The initial definition of
Table 2 Positive predictive values of cancer-related admissions categorized by indication for admission
Admission indication



















Reviewed True + False +
Intent-chemotherapy 6,985 (14.6%) 67,330 (89.8%) 1,428 (4.7%) 1,824 (4.5%) 224 (2.4%) 54,125# 53,932 193 99.6% (99.6–99.7%)
N = 77,791
Intent-procedure 20,188 (42.2%) 1,585 (2.1%) 3,968 (13.2%) 3,258 (8.0%) 1,836 (19.8%) 45,855^ 45,249 606 98.7% (98.6–98.8%)
N = 30,835
Intent-infection 3,017 (6.3%) 249 (<1%) 23,468 (77.8%) 3,646 (9.0%) - 28,887 28,255 632 97.8% (98.6–97.9%)
N = 30,380
Non-infection toxicities 9,607 (20.1%) 499 (<1%) 1,305 (4.3%) 31,997 (78.6%) - 39,485 38,565 920 97.7% (97.5–97.8%)
N = 43,408
Undefined 8,056 (16.8%) 5,292 (7.1%) - - 7,233 (77.8%)
N = 20,581
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missions with chemotherapy delivered in the first 2 days
of hospitalization. However, only 79% of admissions with a
primary CCS diagnosis of chemotherapy were included, an
unexpectedly low proportion. Several states did not report
dates of procedures, resulting in 10,562 (14.1%) admissions
in this group without a date of chemotherapy delivery.
Therefore, the Intent-Chemotherapy definition was modi-
fied to include admissions with chemotherapy delivery as
the CCS group of the primary procedure, which added
7,869 admissions to Intent-Chemotherapy. Of the Intent-
Chemotherapy admissions with an identifiable date of
chemotherapy administration, 77.4% (N = 54,125) received
chemotherapy on Day 0 of hospitalization, 16.2% (N =
11,315) on Day 1 and 5.61% (N = 3,923) on Day 2. In
a few admissions (N = 193, <1%) the date of chemo-
therapy was recorded as negative and these were con-
sidered false positives. Chemotherapy procedure codes
were included in an additional 10,583 admissions not
classified as Intent-Chemotherapy. In these admissions,
the median first day of chemotherapy was hospital Day 5
(range Day 3–172).
Intent-Procedure admissions were identified from the
remaining cancer cohort. Both ICD-9 procedure codes
and primary ICD-9 diagnostic codes (Table 2) from ad-
missions in this indication category were reviewed. A total
of 50,225 procedures were performed in the first 2 days of
the 30,835 admissions identified (average 1.4 procedures
per admission, range 1–14). The 10 most frequent proce-
dures associated with these admissions are listed in
Table 3. Of the 606 (1.3%) procedures not associated withTable 3 Most common ICD-9 procedure codes in the first







41.31 5,185 (10.3%) Biopsy of bone marrow
38.93 4,066 (8.1%) Venous catheterization, not elsewhere
classified
01.59 3,160 (6.3%) Other excision or destruction of lesion
or tissue of brain
03.31 2,705 (5.4%) Spinal tap
86.07 2,264 (4.5%) Insertion of totally implantable vascular
access device [VAD]
85.05 1,147 (2.3%) Incision with removal of foreign body or
device from skin and subcutaneous tissue
02.2 1,076 (2.1%) Ventriculostomy
40.11 1,038 (2.1%) Biopsy of lymphatic structure
40.3 827 (1.7%) Regional lymph node excision
54.4 819 (1.6%) Excision or destruction of peritoneal
tissue
^50,225 procedures representing 1,036 individual ICD-9 procedure codes.cancer or treatment, 571 were appendectomy (47.xx) and
35 were umbilical vein catheterization (38.92).
Intent-Infection admissions were then identified from
the remaining cancer cohort and ICD-9 codes of all pri-
mary and secondary diagnoses reviewed. Cytopenias, par-
ticularly neutropenia, were the primary diagnostic codes
of 12% of the Intent-Infection admissions, and malignancy
accounted for another 10% (Table 2). The most frequent
primary and secondary ICD-9 codes attributed to CCS
groups categorized as infections are presented in Table 4.
The most frequent secondary ICD-9 codes for these ad-
missions varied slightly from those of the primary infec-
tion diagnosis (Table 4). Codes for fever, device infection,
pneumonia, bacteremia, and upper respiratory tract infec-
tions were common regardless of whether the infection
was the primary or secondary diagnosis. Codes listed
only in primary infection diagnoses (i.e., septicemia and
influenza) were the 11th and 20th (respectively) sec-
ondary diagnoses. Conversely, urinary tract infections and
C. difficile infections were the 11th and 13th most com-
mon primary diagnoses. A notable exception was candid-
iasis of the mouth: despite it being the 5th most common
secondary infection diagnosis, it was the 90th most com-
mon primary infection diagnosis. ICD-9 codes for infec-
tions were associated with 659 Intent-Toxicity admissions
and 91 Undefined/Other admissions resulting in a sensi-
tivity of 97.4% (95% CI, 97.2–97.6%).
The final admission indication to be identified was
Intent-Toxicity. Again, ICD-9 codes of primary and sec-
ondary diagnoses were reviewed. The most common first
and second ICD-9 codes in Intent-Toxicity (Table 5) dem-
onstrated that cytopenias remained a common diagnosis
even after removing those admissions with an infection as
the secondary diagnosis. Of the 51% of admissions in this
indication with a primary diagnosis code describing a cy-
topenia, the secondary diagnosis was malignancy in 79%
or a second cytopenia in 15.8%. Non-infectious toxicity
ICD-9 codes were associated with 491 Intent-Infection ad-
missions and 510 Undefined/Other admissions, resulting
in a sensitivity of 97.5% (95% CI, 97.3–97.6%).
After accounting for the four predefined indications for
admission, 20,581 admissions (10.1%) remained unclassi-
fied. Only 35% of these had a primary diagnosis with a
CCS category of “other”. ICD-9 V578.9 (Care involving
other specified rehabilitation procedures) was the most fre-
quent code and was associated with 509 admissions. Five
of the 10 most frequent diagnostic codes were maternal/
fetal in nature (ICD-9 648.91, 664.01, V300.0, 659.71, and
645.11). Almost 17% of admissions with malignancy and
7% of admissions with chemotherapy as the CCS category
of the primary diagnosis remained unclassified by this al-
gorithm. For admissions with malignancy as a primary
code, malignancy was the second diagnostic code in 38.7%
and “other” in 61.1%.
Table 4 Most common ICD-9 diagnosis codes observed in Intent-Infection admissions
Intent-Infection
CCS category of primary diagnosis of infection^ CCS category of primary diagnosis of malignancy or non-infectious toxicity












780.6 3,316 (14.6%) Fever and other physiologic disturbances
of temperature regulation
780.61 951 (13.8%) Fever
996.62 2,586 (11%) Infection and inflammatory reaction due
to other vascular device, implant, and graft
780.6 903 (13.1%) Fever and other physiologic disturbances
of temperature regulation
486 1,671 (7.2%) Pneumonia, organism unspecified 790.7 585 (8.5%) Bacteremia
780.60 1,522 (6.5%) Fever, unspecified 486 506 (7.4%) Pneumonia, organism unspecified
790.7 1,392 (5.9%) Bacteremia 112.0 291 (4.2%) Candidiasis of mouth
999.31 907 (3.9%) Infection due to central venous
catheter
996.62 285 (4.1%) Infection and inflammatory reaction due
to other vascular device, implant, and graft
038.9 744 (3.2%) Unspecified septicemia 599.0 279 (4.1%) Urinary tract infection, site not specified
465.9 710 (3.0%) Acute upper respiratory infections
of unspecified site
008.45 233 (3.4%) Intestinal infection due to Clostridium difficile
079.99 638 (2.7%) Unspecified viral infection 780.60 208 (3.0%) Fever, unspecified
487.1 613 (2.6%) Influenza with other respiratory
manifestations
465.9 156 (2.3%) Acute upper respiratory infections of
unspecified site
^Includes 475 individual ICD-9 diagnosis codes.
&Includes 322 individual ICD-9 diagnosis codes.
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Mean resource utilization, and frequency of HCT, ICU
use, and death were compared across admission indica-
tions (Figure 2). Significant differences (p < 0.001) between
measures of utilization occurred in each comparison.
Intent-Procedure admissions were associated with higherTable 5 Most common ICD-9 diagnosis codes observed in Inte
Intent-To







288.0 8,109 (24.4%) Neutropenia 284.8
288.00 5,351 (16.1%) Neutropenia NOS 331.4
284.8 1,920 (5.8%) Other specified aplastic anemias 288.0
288.03 1,349 (4.1%) Drug induced neutropenia 780.3
276.51 1,195 (3.6%) Dehydration 287.5
276.5 658 (2.0%) Volume depletion 284.1
780.39 616 (1.9%) Other convulsions 288.0
996.85 433 (1.2%) Complications of transplanted
bone marrow
276.1
787.01 393 (1.2%) Nausea with vomiting 285.9
284.1 371 (1.1%) Pancytopenia 518.8
577.0 369 (1.1%) Acute pancreatitis 996.8
&Includes non-infectious ICD-9 codes from CCS diagnostic group 237.
^Includes 760 individual ICD-9 diagnostic codes.
#Includes 547 individual ICD-9 diagnostic codes.mean costs of hospitalization, longer hospital stays, and
higher costs per day compared with other admission indi-
cations. Rates of ICU use and death were significantly
lower in Intent-Chemotherapy than in other indications.
The frequency of HCT procedures was highest in Intent-
Chemotherapy admissions and Intent-Toxicity admissions.nt-Toxicity admissions
xicity
S category of primary diagnosis of malignancy or chemotherapy
CCS category of secondary diagnosis of non-infection toxicity#
diagnosis N = 10,106
n (%)
Description
806 (8.0%) Other specified aplastic anemias
734 (7.3%) Obstructive hydrocephalus
706 (7.0%) Neutropenia
9 507 (5.0%) Other convulsions
437 (4.3%) Thrombocytopenia, unspecified
330 (3.3%) Pancytopenia
0 232 (2.3%) Neutropenia NOS
200 (2.0%) Hyposmolality and/or hyponatremia
195 (1.9%) Anemia, unspecified
1 192 (1.9%) Acute respiratory failure
5 188 (1.9%) Complications of transplanted bone marrow
Figure 2 Comparison of resource utilization measures between admission indication categories for all KID cancer-related admissions
from 2003, 2006, and 2009. Mean length of stay (A), total costs per hospitalization (B) and cost per day (C) were significantly different (p < 0.001).
Similarly, the proportion of admissions including hematopoietic stem cell transplantation (D), the mean day of the transplant procedure (D, squares),
admissions requiring intensive care (E), and death (F) were significantly different (p < 0.001). I:C indicates Intent-Chemotherapy; I:P, Intent-Procedure;
I:I, Intent-Infection; I:T, Intent-Toxicity; U, Undefined and other admissions.
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Chemotherapy (Day 7.8) compared with Intent-Toxicity
admissions (Day 10.6).
Discussion
This report describes a method of stratifying childhood
cancer admissions into clinically meaningful reasons foradmission. We used the externally developed CCS classi-
fication scheme based on ICD-9, which includes a com-
bination of diagnostic and procedure codes, and used
the secondary diagnostic codes when primary diagnostic
codes were inadequate. We validated the use of the CCS
classification scheme in our algorithm against the ICD-9
codes, and compared resource utilization between the
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report to consider childhood cancer admissions in this
framework.
HCUP estimated that 94,600 cancer-related admissions
in 2009 cost approximately $1.9 billion [2], a substantial
proportion of US pediatric healthcare expenditure. Fur-
thermore, the healthcare resource needs of each cancer
diagnosis grew at appreciably different rates during the
2000s [2,3]. Translating such findings into strategies to
improve care delivery has been slow because of a paucity
of studies of patterns of inpatient care in complex dis-
eases. Our method provides a framework for analyzing ad-
ministrative data in a clinically meaningful manner.
Our method for defining a cancer-related admission
cohort from the entire KID admission dataset was simi-
lar to that presented in HCUP’s 2012 report on the same
topic [2], with the exception of CCS groups 44 and 45.
We excluded CCS group 44 (“Neoplasms of unspecified
nature or uncertain behavior”) because of the predomin-
ance of rare and benign neoplasms included in this CCS
group. CCS 45 (“Maintenance chemotherapy”) was also
excluded from the definition of our cancer cohort to
limit the inclusion of a small subset of patients receiving
chemotherapy for non-malignant disorders. We chose
not to assess the sensitivity or negative predictive value
of our approach in the 9.3 million non-cancer-related
admissions because the sheer number of admissions was
so large that both values were expected to be high.
The CCS categorization is designed and managed by
HCUP and included in their data sets. This method has
the distinct benefits of identifying cohorts of similar ICD-9
codes and adjustments for year to year code changes [22].
CCS groups are already included in the HCUP data-
sets, but the categorization software is available from
HCUP and applicable to other platforms, enhancing the
generalizability of this algorithm. In most scenarios of our
analysis, the CCS groups adequately captured our desired
diagnoses and procedures. However, there were scenarios,
such as CCS diagnosis group 237, where the ICD-9 codes
were distributed between categories. In the case of CCS
group 237 we divided the group for better predictive
value, but in other scenarios we allowed a loss of sensitiv-
ity because there were so few admissions with each ICD-9
code.
Our framework presupposes that the timing of proce-
dures and discharge diagnoses can predict a general rea-
son for admission, and, furthermore, that care would be
more similar within each indication than between indi-
cations. Such suppositions are supported by the differ-
ences in overall utilization measures. Further, the lower
rates of deaths and ICU services in admissions intended
to deliver chemotherapy compared with other indica-
tions likely reflect a healthier patient population, i.e., ad-
mitted for pre-planned treatment after meeting healthrequirements rather than admitted in an emergency.
HCT procedures, which require advanced planning and
a relatively good state of patient health, occurred more fre-
quently and earlier in the course of Intent-Chemotherapy
admissions as compared with other admission indications.
While more analysis is needed to understand the variation
within each admission indication, the significant variation
between admission indications supports our categorization
of admissions.
The algorithm provides a framework for the majority of
admissions. However, there remain approximately 13,000
admissions (6.4%) with either malignancy or chemother-
apy toxicity as a primary discharge diagnosis that do not
fit into the framework. In addition, cytopenias without a
more explanatory secondary diagnosis constituted a large
proportion of the Intent-Toxicity admissions. Future ana-
lyses should consider if these admissions represent an in-
dication subset that our framework failed to capture or if
they are a product of the limitations of using discharge
codes [19,21,24,30]. The lack of procedure dates by several
states participating in KID suggests that we may have
under-identified the admissions for procedures. We were
able to adjust our definition of chemotherapy because of
a limited number of codes, but such adjustment for
over 1,000 procedure codes would be impractical and
imprecise. Although some admissionsremained undefined
after application of our algorithm, the admission indi-
cation categories translate to clinical practice with
greater ease than grouping admissions solely by the pri-
mary diagnosis.
Patients within KID are de-identified, a structural aspect
of the database which limits identification of other poten-
tially high utilization events such as de novo diagnosis of
cancer [13]. Because we could not link de-identified admis-
sion data with patients’ medical records or other primary
sources, external validation [30] could not be performed.
Furthermore, de-identification prevented the examination
of multiple admissions for the same patient; therefore, no
comparison between the demographics of our cancer-
related admissions and an external source such as the
SEER cancer registry [1,13] was possible. KID provides the
distinct advantage of a large, diverse geographic database
with established methods for estimating national utilization
[31], benefits which outweigh these aforementioned limita-
tions within the context of our goal of studying patterns
and trends in cancer-related inpatient resource utilization
at a national level.
Conclusions
In summary, our multi-step algorithm for categorizing
childhood cancer-related admissions identifies admis-
sions with distinct patterns of resource utilization. Fu-
ture studies could use this algorithm to compare trends in
indications for hospitalizations between childhood cancer
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similar admissions for closer examination. This framework
has potential for application to childhood cancer in other
administrative data sets. Although this algorithm was de-
veloped for childhood cancer, similar algorithms could be
useful for grouping admissions for adult malignancies or
other complex conditions.
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